Biobanking of CSF: International standardization to optimize biomarker development

被引:103
作者
Teunissen, Charlotte E. [1 ]
Tumani, Hayrettin [2 ]
Engelborghs, Sebastiaan [3 ,5 ,6 ]
Mollenhauer, Brit [4 ,7 ]
机构
[1] Vrije Univ Amsterdam, Med Ctr Amsterdam, Dept Clin Chem, Neurochem Lab & Biobank, NL-1007 MB Amsterdam, Netherlands
[2] Univ Hosp Ulm, Dept Neurol, Lab CSF Diagnost & Clin Neurochem, Ulm, Germany
[3] Univ Antwerp, Reference Ctr Biol Markers Dementia BIODEM, B-2020 Antwerp, Belgium
[4] Paracelsus Elena Klin, Kassel, Germany
[5] Hosp Network Antwerp ZNA, Dept Neurol, Antwerp, Belgium
[6] Hosp Network Antwerp ZNA, Memory Clin, Antwerp, Belgium
[7] Univ Med Ctr, Dept Neurosurg & Neuropathol, Gottingen, Germany
关键词
Cerebrospinal fluid; Biobanking; Control groups; Biomarker studies; Quality control; Consensus protocols; CEREBROSPINAL-FLUID BIOMARKER; POSTLUMBAR PUNCTURE HEADACHE; ALZHEIMERS-DISEASE; CHOROID-PLEXUS; IGG SYNTHESIS; GUIDELINES; DIAGNOSIS; SYSTEM; ONSET; MODEL;
D O I
10.1016/j.clinbiochem.2013.12.024
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Cerebrospinal fluid (CSF) reflects pathophysiological aspects of neurological diseases, where neuroprotective strategies and biomarkers are urgently needed. Therefore, biobanking is very relevant for biomarker discovery and evaluation of neurological diseases. Important and unique features of CSF biobanking are intensive collaboration in international networks and the tight application of standardized protocols. The current adoption of standardized protocols for CSF and blood collection as presented in this review enables biomarker studies in large cohorts of patients and controls. Another topic of this review is the selection of control groups, which influences the outcome of biomarker investigations. Control groups in CSF biobanks mainly consist of different disease controls. This is in part due to the fact that lumbar punctures are mostly performed for clinical indications and rarely for research purposes only, as it is a relatively invasive procedure. Moreover, there is a lack of homogenous criteria and definition of control groups. We therefore propose uniform consensus definitions for such control groups in biomarker research, i.e. Healthy controls (HC), Spinal anesthesia subjects (SAS), Symptomatic controls (SC), Inflammatory Neurological Disease Controls (CINDC), Peripheral Inflammatory Neurological Disease Controls (PINDC) and Non-inflammatory Neurological Disease Controls (NINDC). Another important aspect of CSF biobanking is quality control. Systematic studies to address effects of pre-analytical and storage variation on a broad range of CSF proteins are needed. In conclusion, biomarker research in neurodegenerative diseases has entered a new era due to the collaborative and multicenter efforts of many groups. The streamlining of biobanking procedures, including quality control, and the selection of optimal control groups for investigating biomarkers are important improvements to perform high quality biomarker studies. (C) 2014 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:288 / 292
页数:5
相关论文
共 22 条
[1]   Pre-analytical influence on the low molecular weight cerebrospinal fluid proteome [J].
Berven, Frode S. ;
Kroksveen, Ann C. ;
Berle, Magnus ;
Rajalahti, Tarja ;
Flikka, Kristian ;
Arneberg, Reidar ;
Myhr, Kjell-Morten ;
Vedeler, Christian ;
Kvalheim, Olav M. ;
Ulvik, Rune J. .
PROTEOMICS CLINICAL APPLICATIONS, 2007, 1 (07) :699-711
[2]  
BLENNOW K, 1993, ACTA NEUROL SCAND, V88, P221
[3]   Cerebrospinal Fluid Levels of β-Amyloid 1-42, but Not of Tau, Are Fully Changed Already 5 to 10 Years Before the Onset of Alzheimer Dementia [J].
Buchhave, Peder ;
Minthon, Lennart ;
Zetterberg, Henrik ;
Wallin, Asa K. ;
Blennow, Kaj ;
Hansson, Oskar .
ARCHIVES OF GENERAL PSYCHIATRY, 2012, 69 (01) :98-106
[4]   Truncated cystatin C in cerebrospiral fluid: Technical artefact or biological process? [J].
Carrette, O ;
Burkhard, PR ;
Hughes, S ;
Hochstrasser, DF ;
Sanchez, JC .
PROTEOMICS, 2005, 5 (12) :3060-3065
[5]   Guidelines on routine cerebrospinal fluid analysis. Report from an EFNS task force [J].
Deisenhammer, F. ;
Bartos, A. ;
Egg, R. ;
Gilhus, N. E. ;
Giovannoni, G. ;
Rauer, S. ;
Sellebjerg, F. .
EUROPEAN JOURNAL OF NEUROLOGY, 2006, 13 (09) :913-922
[6]   EFNS guidelines on disease-specific CSF investigations [J].
Deisenhammer, F. ;
Egg, R. ;
Giovannoni, G. ;
Hemmer, B. ;
Petzold, A. ;
Sellebjerg, F. ;
Teunissen, C. ;
Tumani, H. .
EUROPEAN JOURNAL OF NEUROLOGY, 2009, 16 (06) :760-770
[7]  
del Campo M, 2012, BIOMARK MED, V6, P419, DOI [10.2217/BMM.12.46, 10.2217/bmm.12.46]
[8]  
Greitz D, 1996, AM J NEURORADIOL, V17, P431
[9]   Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers [J].
Jack, Clifford R., Jr. ;
Knopman, David S. ;
Jagust, William J. ;
Petersen, Ronald C. ;
Weiner, Michael W. ;
Aisen, Paul S. ;
Shaw, Leslie M. ;
Vemuri, Prashanthi ;
Wiste, Heather J. ;
Weigand, Stephen D. ;
Lesnick, Timothy G. ;
Pankratz, Vernon S. ;
Donohue, Michael C. ;
Trojanowski, John Q. .
LANCET NEUROLOGY, 2013, 12 (02) :207-216
[10]   Validation of Assays for Measurement of Amyloid-β Peptides in Cerebrospinal Fluid and Plasma Specimens from Patients with Alzheimer's Disease Treated with Solanezumab [J].
Lachno, D. Richard ;
Evert, Barbara A. ;
Vanderstichele, Hugo ;
Robertson, Michael ;
DeMattos, Ronald B. ;
Konrad, Robert J. ;
Talbot, Jayne A. ;
Racke, Margaret M. ;
Dean, Robert A. .
JOURNAL OF ALZHEIMERS DISEASE, 2013, 34 (04) :897-910